The Prognostic Impact of CDKN2A/B Hemizygous Deletions in IDH-Mutant Glioma

Medicine, Neurology, Oncology,
glioma   IDH mutation   CDKN2A/B deletion   prognosis   neuro-oncology  

Background Introduction Glioma is one of the most common primary tumors of the central nervous system, and its prognosis and treatment methods vary significantly depending on molecular characteristics. In recent years, with the advancement of molecular pathology, IDH (isocitrate dehydrogenase) mutations have been identified as important molecular m...

Reappraisal of Prognostic Factors in CNS WHO Grade 3 Oligodendrogliomas IDH-Mutant and 1p/19q Co-Deleted: Lessons from the French POLA Cohort

Medicine, Neurology, Oncology,
oligodendroglioma   prognostic factors   IDH mutation   1p/19q co-deletion   French POLA cohort   pathological groups   contrast enhancement  

Reappraisal of Prognostic Factors in CNS WHO Grade 3 Oligodendrogliomas: Insights from the French POLA Cohort Academic Background Oligodendroglioma is a relatively rare primary brain tumor in the central nervous system (CNS), characterized by IDH gene mutations and 1p/19q co-deletion. According to the World Health Organization (WHO) classification ...

IDH Mutation, Glioma Immunogenicity, and Therapeutic Challenge of Primary Mismatch Repair Deficient IDH-Mutant Astrocytoma (PMMRDIA): A Systematic Review

Medicine, Neurosurgery, Oncology, Life Sciences, Immunology,
IDH mutation   glioma   immunogenicity   mismatch repair deficiency   astrocytoma   therapeutic challenge   systematic review  

Immunogenicity and Therapeutic Challenges of IDH-Mutant Gliomas Background Glioma is a common central nervous system tumor, and its treatment and prognosis vary significantly depending on molecular characteristics. In recent years, the diagnostic and prognostic significance of isocitrate dehydrogenase (IDH) mutations in gliomas has been increasingl...